In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DFINE Seeks Meaning Outside Of Spine

Executive Summary

Privately held DFINE Inc., a supplier of tools for treating vertebral compression fractures in the spine, is trying to reposition itself from being a spine company to an “interventionalist company” that provides tools necessary to interventional radiologists, neuroradiologists, and oncologists.

You may also be interested in...

Sober NASS Reflects Challenges Facing Spine Industry

This years’ gathering of the North American Spine Society (NASS) carried a muted tone that befits a stagnant or shrinking industry. Surgeons in NASS’ leadership spoke to the minimal growth in their own reimbursements and their concerns over how changes in the health care sector will impact the specialty going forward.

VCF Market: Interest Remains High As Market Share Shifts

Although the spine market appears to be stabilizing to some extent, the vertebral compression fracture market continues to be challenged by reimbursement issues and lingering controversy stemming from the New England Journal of Medicine articles questioning the efficacy of vertebroplasty and vertebral augmentation as a treatment for VCFs.

Are Device VCs Becoming Spineless?

Increasing concerns over the cost and efficacy of spinal procedures have chilled VC interest in spine companies, once the hot growth area in orthopedics. So, if spine is not the answer, where will VCs find investment opportunities in orthopedics, which remains one of the largest device sectors?

Related Content


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts